Oral Ketamine for Depression: New RCT + Meta-Analysis
How effective is oral ketamine for depression, really? A 2025 study published in the Journal of Affective Disorders set out to answer that question with both a new randomized controlled trial and a comprehensive meta-analysis pooling data from multiple studies. The answer: oral ketamine works, and the numbers put it ahead of many standard antidepressants.
The Study Design
This research took a two-pronged approach. First, the investigators conducted a new RCT comparing oral ketamine to placebo in patients with major depressive disorder (MDD) and bipolar disorder. Second, they performed a meta-analysis incorporating their results alongside data from previously published oral ketamine trials. This combined methodology provides both fresh clinical evidence and a broader statistical picture of oral ketamine's efficacy.
Participants in the RCT had moderate to severe depression and were assessed using validated rating scales at multiple time points throughout the treatment period. The meta-analysis drew from randomized, placebo-controlled trials of oral ketamine for depressive disorders, applying rigorous inclusion criteria to ensure data quality.
The Key Number: NNT of 4.6
The most striking finding was the number needed to treat (NNT) of 4.6. For those unfamiliar with this metric, NNT answers a simple question: how many patients need to receive the treatment for one additional patient to benefit compared to placebo?
An NNT of 4.6 means that for roughly every five patients treated with oral ketamine, one additional patient experiences a clinically meaningful response that would not have occurred with placebo alone. In clinical medicine, this is considered a strong effect.
To put this in context, consider how oral ketamine compares to medications most people are familiar with:
- SSRIs for depression: NNT of approximately 7-8, meaning you need to treat 7-8 patients to see one additional responder
- Oral ketamine: NNT of 4.6
- Isha Health's real-world outcomes: An 88.8% improvement rate across 546 patients, which reflects the added benefit of combining ketamine with clinical support and therapy integration
The lower the NNT, the more effective the treatment. Oral ketamine's NNT of 4.6 places it among the more effective interventions available for depression.
Effectiveness Across Diagnoses
An important aspect of this study is that it included patients with both major depressive disorder and bipolar depression. Bipolar depression is notoriously difficult to treat — many standard antidepressants carry risks of triggering manic episodes, and the medication options that are considered safe often have limited efficacy.
The meta-analysis found oral ketamine effective across both diagnostic categories, suggesting that the drug's mechanism of action — primarily through NMDA receptor modulation and downstream effects on neuroplasticity — operates through pathways that are relevant regardless of whether depression occurs in a unipolar or bipolar context.
What This Means for Patients
For patients who have tried SSRIs, SNRIs, or other conventional antidepressants without adequate relief, these findings reinforce what many clinicians have observed in practice: oral ketamine offers a meaningfully different treatment option with stronger response rates.
The NNT data also helps address a common concern. Patients sometimes wonder whether the positive reports about ketamine are driven by hype rather than evidence. A meta-analysis that pools data from multiple rigorous trials and arrives at an NNT of 4.6 provides the kind of statistical grounding that both patients and clinicians can rely on.
It is worth noting that oral ketamine is not FDA-approved for depression and is used off-label. However, the growing body of RCT evidence — including this 2025 publication — continues to build the case for its efficacy and safety.
How Oral Ketamine Compares to Other Ketamine Routes
Patients exploring ketamine therapy often encounter multiple delivery options: IV infusions, nasal esketamine (Spravato), and oral or sublingual formulations. This meta-analysis focused specifically on oral ketamine and found robust efficacy, adding to the evidence that patients do not necessarily need IV administration to benefit from ketamine's antidepressant effects.
For a detailed comparison, see our breakdown of oral ketamine vs IV infusion. For patients weighing ketamine against traditional antidepressants, our article on ketamine vs SSRIs explores the differences in mechanism, onset, and side effect profiles.
Moving Forward with the Evidence
This study strengthens the evidence base for oral ketamine as a treatment for depression. Combined with real-world outcomes data — like the results from Isha Health's clinical practice — it paints an increasingly clear picture: oral ketamine is an effective, well-tolerated option for patients who have not responded to conventional treatments.
Learn more about ketamine therapy for depression or explore Isha Health's online ketamine therapy program.
Related Articles
Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.
88.8% of Isha Health patients with moderate-to-severe depression show measurable improvement
Based on 546 patients and 1,900+ validated assessments. See our clinical outcomes →
